LGVN Q3 2023 Earnings — Longeveron Inc. Revenue & Financial Results | Market Cap Arena

LGVNLongeveron Inc.

$20M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$150,000-43.4% YoY

Gross Profit

$54,00036.0% margin

Operating Income

-$5M-3440.7% margin

Net Income

-$5M-3404.0% margin

EPS (Diluted)

$-2.79

QoQ Revenue Growth

-30.9%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$499,000

Balance Sheet

Total Assets

$12M

Total Liabilities

$5M

Stockholders' Equity

$7M

Cash & Equivalents

$2M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$150,000	$265,000	-43.4%
Gross Profit	$54,000	$92,000	-41.3%
Operating Income	-$5M	-$5M	+0.5%
Net Income	-$5M	-$5M	+2.6%